The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1441
ISSUE1441
April 28, 2014
Conjugated Estrogens/Bazedoxifene (Duavee) for Menopausal Symptoms and Prevention of Osteoporosis
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Conjugated Estrogens/Bazedoxifene (Duavee) for Menopausal Symptoms and Prevention of Osteoporosis
April 28, 2014 (Issue: 1441)
The FDA has approved Duavee (Pfizer), a fixed-dose
combination of conjugated estrogens and the
new selective estrogen receptor modulator (SERM)
bazedoxifene, for treatment of moderate to severe
vasomotor symptoms and for prevention of...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.